ATE120954T1 - Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids. - Google Patents

Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.

Info

Publication number
ATE120954T1
ATE120954T1 AT92306646T AT92306646T ATE120954T1 AT E120954 T1 ATE120954 T1 AT E120954T1 AT 92306646 T AT92306646 T AT 92306646T AT 92306646 T AT92306646 T AT 92306646T AT E120954 T1 ATE120954 T1 AT E120954T1
Authority
AT
Austria
Prior art keywords
aids
treatment
produce
fatty acids
medicinal product
Prior art date
Application number
AT92306646T
Other languages
English (en)
Inventor
David Frederick Horrobin
Michael David C O Efam Winther
Park Po Box Industrial
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10698951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE120954(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE120954T1 publication Critical patent/ATE120954T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Amplifiers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT92306646T 1991-07-24 1992-07-20 Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids. ATE120954T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116054A GB9116054D0 (en) 1991-07-24 1991-07-24 Preparation of fatty acid medicaments

Publications (1)

Publication Number Publication Date
ATE120954T1 true ATE120954T1 (de) 1995-04-15

Family

ID=10698951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92306646T ATE120954T1 (de) 1991-07-24 1992-07-20 Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.

Country Status (12)

Country Link
EP (1) EP0524796B1 (de)
JP (1) JPH05194244A (de)
KR (1) KR930001902A (de)
AT (1) ATE120954T1 (de)
AU (1) AU1968992A (de)
CA (1) CA2073913A1 (de)
DE (1) DE69202019D1 (de)
FI (1) FI923357A (de)
GB (1) GB9116054D0 (de)
IE (1) IE922250A1 (de)
NO (1) NO922936L (de)
ZA (1) ZA925562B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
DE19611953A1 (de) * 1996-03-26 1997-10-02 Beiersdorf Ag Verwendung von ungesättigten Monocarbonsäuren gegen Superinfektionen
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
EP1597978A1 (de) 2004-05-17 2005-11-23 Nutricia N.V. Synergie von GOS und polyfruktose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
MXPA06015071A (es) * 2004-06-22 2007-08-06 Nutricia Nv Mejoramiento de la integridad de barrera con acidos grasos en pacientes con vih.
JP2006282644A (ja) * 2005-04-05 2006-10-19 Idemitsu Kosan Co Ltd 疲労回復剤
MY163134A (en) 2006-03-15 2017-08-15 Suntory Holdings Ltd Composition containing riboflavin and sesamin-class compounds
WO2008094510A2 (en) 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
SG179481A1 (en) 2007-03-15 2012-04-27 Suntory Holdings Ltd Anti-fatigue agent
CN101835374B (zh) 2007-07-09 2014-08-27 东弗吉尼亚医学院 具有抗病毒和抗微生物性质的取代的核苷衍生物
JP2009073747A (ja) * 2007-09-19 2009-04-09 Suntory Ltd アラキドン酸を有効成分とする抗疲労剤
KR101528380B1 (ko) 2007-09-19 2015-06-11 산토리 홀딩스 가부시키가이샤 세사민류와 아라키돈산류를 함유하는 조성물
WO2020077420A1 (en) * 2018-10-16 2020-04-23 MOREIRA, Nivaldo José Extract of jatropha curcas seed oil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen

Also Published As

Publication number Publication date
FI923357A (fi) 1993-01-25
KR930001902A (ko) 1993-02-22
CA2073913A1 (en) 1993-01-25
ZA925562B (en) 1993-04-28
NO922936L (no) 1993-01-25
GB9116054D0 (en) 1991-09-11
IE922250A1 (en) 1993-01-27
EP0524796B1 (de) 1995-04-12
JPH05194244A (ja) 1993-08-03
NO922936D0 (no) 1992-07-23
DE69202019D1 (de) 1995-05-18
AU1968992A (en) 1993-01-28
FI923357A0 (fi) 1992-07-23
EP0524796A1 (de) 1993-01-27

Similar Documents

Publication Publication Date Title
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
DE69317433D1 (de) Ungesättigte aliphatische dicarbonsäuren
ATE264676T1 (de) Verwendung von dha in der behandlung von dyslexie
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE69550T1 (de) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
ATE135223T1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE3856052T2 (de) Anwendung des N-n-butyl-Derivates von Desoxynojirimycin zur Herstellung eines Arzneimittels zur Inhibierung von HIV-Virus
ATE192929T1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
ATE160090T1 (de) Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
ATE183390T1 (de) Verwendung einer kombination von antineoplastonen zur herstellung eines arzneimittels zur behandlung der neurofibromatose
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
ATE76302T1 (de) Verwendung von einer immunstimulanten biologisten substanz zur herstellung eines medikaments zur behandlung des menschlichen immunschwaechevirus.
ATE129636T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties